Schizophrenia is a psychiatric disease that affects around 1% of the world's population, and comprises a number of heterogeneous symptoms complicating treatment. Above all, several environmental and genetic factors influence its etiology and, therefore, diagnosing the disease before it manifests itself is a further step towards treatment, characterizing this group in UHR (ultra high risk), a prodrome profile of the disease that may or may not to manifest. The interest in this group is to find biological markers that can predict the disease and increasingly understand its etiology, so researchers study the inflammatory processes in schizophrenia and have already noticed the irregular presence of some cytokines. Our interest is to find peripheral biomarkers that guide us to identify processes that are compromised by the etiology of the disease, the inflammatory process during the disease period seems to be compromised and our study will study the inflammatory pathway of COX-2, this is a pathway induced by other inflammatory processes such as cytokines and we will associate these inflammatory markers between them and analyze them in UHR and converted schizophrenic patients.The methodology to be performed will be a lipid metabolomics used for analysis of the COX-2 pathway and made through a mass spectrometer associated to liquid chromatography identifying our target markers, an extremely specific technique with great sensitivity for detection of molecules. And together we will do the immunofluorescence technique of COX-2-related cytokines to quantify specific cytokines and see interactions of both inflammatory markers if it is altered both in the prodromal phase and in the phase of psychotic disorders.
News published in Agência FAPESP Newsletter about the scholarship: